Motus GI to Present at the Oppenheimer 28th Annual Healthcare Conference
March 13 2018 - 8:35AM
Business Wire
- Presentation with live audio webcast to be
held Tuesday, March 20 at 3:20 p.m. ET -
Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus" or the
"Company"), a medical technology company dedicated to improving
endoscopy outcomes and experiences, announced today that Mark
Pomeranz, CEO, will present at the Oppenheimer 28th Annual
Healthcare Conference in New York City on Tuesday, March 20, 2018
at 3:20 p.m. ET.
Mr. Pomeranz will provide a corporate update and discuss the
Company's strategy for its flagship product, the Pure-Vu® System.
The Pure-Vu System works with standard colonoscopes to help
facilitate the cleaning of poorly prepped colons during the
colonoscopy procedure, while preserving standard procedural
workflow and techniques. Pure-Vu’s unique capability to cleanse the
colon intra-procedurally may reduce the sole dependency on the
pre-procedural preparation that many patients find difficult to
tolerate, especially patients with medical issues and those that
need a colonoscopy in an emergent situation. The Pure-Vu System
received 510(k) clearance from the U.S. Food and Drug
Administration and CE mark approval in Europe, and is currently
being introduced on a pilot basis in the U.S.
In addition to the presentation, management will be available to
participate in one-on-one meetings with qualified members of the
investor community who are registered to attend the conference.
A live audio webcast of the presentation will be accessible on
the Events page of the Investors section on the Company's website
at www.motusgi.com. The webcast replay will be available
approximately two hours after the presentation ends and will be
accessible for 90 days.
About Motus GI
Motus GI Holdings, Inc. is a medical technology company, with
subsidiaries in the U.S. and Israel, dedicated to improving
endoscopy outcomes, lowering costs and enhancing patient
experiences. The Company is focused on the development and
commercialization of the Pure-Vu® System to improve the colonoscopy
experience and assist in the early detection and prevention of
colorectal cancer and other diseases of the rectum and colon.
For more information, visit www.motusgi.com and connect with the
Company on Twitter, LinkedIn, and Google+.
Forward-Looking Statements
This press release contains certain forward-looking statements.
Forward-looking statements are based on the Company's current
expectations and assumptions. The Private Securities Litigation
Reform Act of 1995 provides a safe-harbor for forward-looking
statements. These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
"expect," "anticipate," "intend," "plan," "believe," "estimate,"
"potential," "predict," "project," "should," "would" and similar
expressions and the negatives of those terms. Prospective investors
are cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date of this presentation.
The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Important factors that could cause
actual results to differ materially from those in the
forward-looking statements are set forth in the Company's filings
with the Securities and Exchange Commission, including its
registration statement on Form S-1, as amended from time to time,
under the caption "Risk Factors."
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180313005411/en/
Investors:Jenene Thomas
Communications, LLCJenene Thomas,
908-938-1475jtc@jtcir.comorMedia:6 Degrees PRTony Plohoros,
908-940-0135tplohoros@6degreesPR.com
Motus GI (NASDAQ:MOTS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Motus GI (NASDAQ:MOTS)
Historical Stock Chart
From Sep 2023 to Sep 2024